[1] |
RIAZI K, AZHARI H, CHARETTE JH, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2022, 7( 9): 851- 861. DOI: 10.1016/S2468-1253(22)00165-0.
|
[2] |
PAIK JM, HENRY L, YOUNOSSI Y, et al. The burden of nonalcoholic fatty liver disease(NAFLD) is rapidly growing in every region of the world from 1990 to 2019[J]. Hepatol Commun, 2023, 7( 10): e0251. DOI: 10.1097/HC9.0000000000000251.
|
[3] |
LING Z, ZHANG CC, HE J, et al. Association of healthy lifestyles with non-alcoholic fatty liver disease: A prospective cohort study in Chinese government employees[J]. Nutrients, 2023, 15( 3): 604. DOI: 10.3390/nu15030604.
|
[4] |
HUANG DQ, NOUREDDIN N, AJMERA V, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: An individual participant-level data meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023, 8( 9): 829- 836. DOI: 10.1016/S2468-1253(23)00157-7.
|
[5] |
JULIÁN MT, BALLESTA S, PERA G, et al. Abdominal obesity and dsyglycemia are risk factors for liver fibrosis progression in NAFLD subjects: A population-based study[J]. Front Endocrinol(Lausanne), 2022, 13: 1051958. DOI: 10.3389/fendo.2022.1051958.
|
[6] |
DUAN D, KIM LJ, JUN JC, et al. Connecting insufficient sleep and insomnia with metabolic dysfunction[J]. Ann N Y Acad Sci, 2023, 1519( 1): 94- 117. DOI: 10.1111/nyas.14926.
|
[7] |
National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
|
[8] |
HU Y, LI HJ, ZHANG H, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial[J]. Nat Commun, 2023, 14( 1): 6409. DOI: 10.1038/s41467-023-42162-0.
|
[9] |
ZHAO JJ, WANG QY, ZHAO XY, et al. Electro-acupuncture reduced steatosis on MRI-PDFF in patients with non-alcoholic steatohepatitis: A randomized controlled pilot clinical trial[J]. Chin Med, 2023, 18( 1): 19. DOI: 10.1186/s13020-023-00724-w.
|
[10] |
MOLLAYEVA T, THURAIRAJAH P, BURTON K, et al. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis[J]. Sleep Med Rev, 2016, 25: 52- 73. DOI: 10.1016/j.smrv.2015.01.009.
|
[11] |
NOBLE WS. How does multiple testing correction work?[J]. Nat Biotechnol, 2009, 27( 12): 1135- 1137. DOI: 10.1038/nbt1209-1135.
|
[12] |
ZHOU JH, ZHOU F, WANG WX, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020, 71( 5): 1851- 1864. DOI: 10.1002/hep.31150.
|
[13] |
ZHOU F, ZHOU JH, WANG WX, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and meta-analysis[J]. Hepatology, 2019, 70( 4): 1119- 1133. DOI: 10.1002/hep.30702.
|
[14] |
YOUNOSSI ZM, COREY KE, LIM JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review[J]. Gastroenterology, 2021, 160( 3): 912- 918. DOI: 10.1053/j.gastro.2020.11.051.
|
[15] |
WANG CE, XU WT, GONG J, et al. Research progress in the treatment of non-alcoholic fatty liver disease[J]. Clin J Med Offic, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
王彩娥, 许文涛, 宫建, 等. 非酒精性脂肪性肝病治疗研究进展[J]. 临床军医杂志, 2022, 50( 9): 897- 899, 903. DOI: 10.16680/j.1671-3826.2022.09.06.
|
[16] |
YU LB, LIN CL, CHEN XH, et al. A meta-analysis of sleep disorders and nonalcoholic fatty liver disease: Potential causality and symptom management[J]. Gastroenterol Nurs, 2022, 45( 5): 354- 363. DOI: 10.1097/SGA.0000000000000658.
|
[17] |
MESARWI OA, LOOMBA R, MALHOTRA A. Obstructive sleep apnea, hypoxia, and nonalcoholic fatty liver disease[J]. Am J Respir Crit Care Med, 2019, 199( 7): 830- 841. DOI: 10.1164/rccm.201806-1109TR.
|
[18] |
WANG HL, GU YQ, ZHENG LX, et al. Association between bedtime and the prevalence of newly diagnosed non-alcoholic fatty liver disease in adults[J]. Liver Int, 2018, 38( 12): 2277- 2286. DOI: 10.1111/liv.13896.
|
[19] |
ZAREAN E, LOOHA MA, AMINI P, et al. Sleep characteristics of middle-aged adults with non-alcoholic fatty liver disease: Findings from the Shahrekord PERSIAN cohort study[J]. BMC Public Health, 2023, 23( 1): 312. DOI: 10.1186/s12889-023-15251-4.
|
[20] |
LIU HW, HUANG SL, XU MD, et al. The association between sleep duration, quality, and nonalcoholic fatty liver disease: A cross-sectional study[J]. Open Med(Wars), 2023, 18( 1): 20230670. DOI: 10.1515/med-2023-0670.
|